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Summary
 
Murine L929 fibrosarcoma cells were transfected with the human Fas (APO-1/CD95) receptor,
and the role of various caspases in Fas-mediated cell death was assessed. Proteolytic activation
of procaspase-3 and -7 was shown by Western analysis. Acetyl-Tyr-Val-Ala-Asp-chlorometh-
ylketone and benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone,
tetrapeptide inhibitors of caspase-1– and caspase-3–like proteases, respectively, failed to block
Fas-induced apoptosis. Unexpectedly, the broad-spectrum caspase inhibitors benzyloxycarbo-
nyl-Val-Ala-Asp(OMe)-fluoromethylketone and benzyloxycarbonyl-Asp(OMe)-fluorometh-
ylketone rendered the cells even more sensitive to Fas-mediated cell death, as measured after 18 h
incubation. However, when the process was followed microscopically, it became clear that
anti-Fas–induced apoptosis of Fas-transfected L929 cells was blocked during the first 3 h, and
subsequently the cells died by necrosis. As in tumor necrosis factor (TNF)-induced necrosis,
Fas treatment led to accumulation of reactive oxygen radicals, and Fas-mediated necrosis was
inhibited by the oxygen radical scavenger butylated hydroxyanisole. However, in contrast to
TNF, anti-Fas did not activate the nuclear factor 
 
k
 
B under these necrotic conditions. These re-
sults demonstrate the existence of two different pathways originating from the Fas receptor, one
rapidly leading to apoptosis, and, if this apoptotic pathway is blocked by caspase inhibitors, a
second directing the cells to necrosis and involving oxygen radical production.
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D
 
epending on the cell type and the stimulus, a cell may
die in either of two distinct ways: apoptosis or necro-
sis. Necrosis is characterized by swelling of the cell and the
organelles, and results in disruption of the cell membrane
and in lysis (1). Release of the cytoplasmic content leads
to an inflammatory response. Apoptosis can be recognized
by membrane blebbing, shrinking and condensing of the
cells and their organelles, internucleosomal degradation of
the DNA, and disintegration of the cell, after which the
fragments are phagocytosed by neighboring cells (2, 3).
Apoptosis occurs at various stages in the life cycle of mul-
ticellular organisms. From embryonic development through
immunological regulation, as well as part of pathological
situations, cell death by apoptosis is the most common
way to eliminate superfluous, inappropriate, or harmful
cells (4). However, inappropriate or defective apoptosis is
the cause of many human diseases (5). Therefore, many
studies aim to elucidate the apoptotic pathways and inter-
actions between proapoptotic and antiapoptotic cellular
components. Although mechanisms signaling to necrosis
cannot be fully explained in molecular terms, apoptosis is
generally believed to be mediated by caspase activation
(6–8).
The TNF receptor type 1 (TNFR-1) and Fas (APO-1/
CD95) are two cell surface receptors sharing structural and
functional homology. Both are characterized by extracellu-
lar repeats of cysteine-rich domains (9), but TNFR-1 and
Fas also have a common intracellular motif, called the
“death domain” (DD),
 
1
 
 of 
 
z
 
80 amino acids (10, 11). These
 
1
 
Abbreviations used in this paper:
 
 Ac-DEVD-amc, acetyl-Asp(OMe)-
Glu(OMe)-Val-Asp(OMe)-aminomethylcoumarin; Ac-YVAD-amc, acetyl-
Tyr-Val-Ala-Asp-aminomethylcoumarin; Ac-YVAD-cmk, acetyl-Tyr-Val-
Ala-Asp-chloromethylketone; BHA, butylated hydroxyanisole; DD, death
domain; DR, death receptor; DHR123, dihydrorhodamine, 123; FADD,
Fas-associated DD protein; L929hFas, Fas-transfected L929 (cells); MORT,
mediator of receptor-induced toxicity; NF-
 
k
 
B, nuclear factor 
 
k
 
B; PI,
propidium iodide; TRADD, TNFR-associated DD protein; TRAIL, TNF-
related apoptosis–inducing ligand; zAAD-cmk, benzyloxycarbonyl-Ala-Ala-
Asp-chloromethylketone; zDEVD-fmk, benzyloxycarbonyl-Asp(OMe)-
Glu(OMe)-Val-Asp(OMe)-fluoromethylketone; zD-fmk, benzyloxycarbo-
nyl-Asp(OMe)-fluoromethylketone; zVAD-afc, benzyloxycarbonyl-Val-
Ala-Asp(OMe)-aminotrifluoromethylcoumarin; zVAD-fmk, benzyloxycar-
bonyl-Val-Ala-Asp(OMe)-fluoromethylketone.
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DDs aggregate after ligand binding, which initiates signaling
to cell death (12–14). The clustered DDs of TNFR-1 recruit
TNFR-associated DD protein (TRADD), which then forms
a docking site for Fas-associated DD protein (FADD)/medi-
ator of receptor-induced toxicity (MORT)1 (15, 16). After
clustering of Fas, FADD directly associates through its own
DD to that of Fas (13, 17, 18). For both TNFR-1 and Fas,
FADD recruits FADD-like IL-1
 
b
 
–converting enzyme
(FLICE)/MORT1-associated CED-3 homologue (MACH)/
procaspase-8 by a homotypic interaction through their so-
called “death effector domain” (19, 20). The COOH-termi-
nal part of procaspase-8 consists of a CPP32/YAMA/caspase-
3–like domain. It is presumed that recruitment of procaspase-8
in the Fas complex after Fas ligand binding results in activation
of procaspase-8 (21), which in turn initiates a procaspase acti-
vation cascade, eventually leading to apoptosis (22–24).
Under normal conditions, Fas triggering has so far only
been reported to result in cell death by apoptosis. But de-
pending on the cell line, activation of the TNFR-1–signal-
ing pathway leads either to apoptotic or to necrotic cell
death (25, 26). Mere trimerization of the TNFR-1 DD is
sufficient for signaling to necrosis of L929 cells (14). The
same intracellular domain mediates both TNF-mediated
necrosis and apoptosis. In contrast to apoptosis, TNF-medi-
ated necrosis is not dependent on caspase activity in L929
cells. On the contrary, inhibition of caspases sensitizes the
cells to TNF cytotoxicity, and this sensitization is corre-
lated with a higher production of reactive oxygen radicals
(27). It has been shown previously that TNF-induced ne-
crosis in L929 cells is preceded by mitochondrial radical
production, and scavenging of these radicals by agents such
as butylated hydroxyanisole (BHA) blocks TNF cytotoxic-
ity (28). There is much evidence that reactive oxygen radi-
cals are the key mediators of necrotic cell death in L929
cells.
In this paper we show that when the apoptotic pathway
induced by Fas triggering in L929 cells is blocked by a
caspase inhibitor, the cells die in a necrotic way, which in-
volves oxygen radicals.
 
Materials and Methods
 
Cells.
 
L929 cells and their TNF-resistant derivatives L929r1
(29) were cultured in DMEM, supplemented with 5% newborn
bovine serum and 5% FBS, penicillin (100 U/ml), streptomycin
(0.1 mg/ml), and 
 
l
 
-glutamine (0.03%).
 
Abs, Cytokines, and Reagents.
 
Recombinant murine TNF was
produced in 
 
Escherichia coli
 
 and purified to 99% homogeneity (30).
The specific activity was 1.4 
 
3 
 
10
 
8
 
 IU/mg as determined in a
standardized cytotoxicity assay on L929 cells. Anti–human Fas
Abs (agonistic Abs: clone CH-11; immunodetection Abs: clone
UB-2) were purchased from ImmunoTech (Marseille, France).
Dihydrorhodamine 123 (DHR123; Molecular Probes, Inc., Eugene,
OR) was prepared as a 5-mM stock solution in DMSO and used
at 1 
 
m
 
M. Propidium iodide (PI; Becton Dickinson, Franklin
Lakes, NJ) was dissolved at 3 mM in PBS and used at 30 
 
m
 
M.
BHA was purchased from Sigma Chemical Co. (St. Louis, MO)
and prepared as a 500-mM stock solution in ethanol.
The caspase peptide inhibitors benzyloxycarbonyl-Asp(OMe)-
Glu(OMe)-Val-Asp(OMe)-fluoromethylketone (zDEVD-fmk), ben-
zyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-
fmk), and benzyloxycarbonyl-Asp(OMe)-fluoromethylketone
(zD-fmk) were purchased from Enzyme Systems Products, Inc.
(Livermore, CA). Acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-
YVAD-cmk) and benzyloxycarbonyl-Ala-Ala-Asp-chlorometh-
ylketone (zAAD-cmk) were supplied by Calbiochem-Novabio-
chem International (San Diego, CA).
Anticytokine response modifier A Abs were provided by Dr.
D. Pickup (Duke University Medical Center, Durham, NC).
Polyclonal Abs against recombinant murine caspases were pre-
pared by the Centre d’Economie Rurale (Laboratoire d’Hormo-
nologie Animale, Marloie, Belgium).
 
Plasmids and Transfections.
 
Human Fas cDNA was provided
by Dr. S. Nagata (Osaka Bioscience Institute, Osaka, Japan), and
was inserted as an XhoI-XbaI fragment in pEF-BOS (31). pPHT,
containing the hygromycin resistance gene, was used as a selec-
tion vector.
 
Cytotoxicity Assays.
 
Cells were seeded on day –1 at 2 
 
3 
 
10
 
4
 
cells/well in 96-well plates. The next day, inhibitors and anti-Fas
(clone CH-11) were added at the given concentrations. Typi-
cally, cells were incubated with anti-Fas for 18 h, and cell viabil-
ity was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide staining as described previously (32). The
percentage of cell survival was calculated as follows: (
 
A
 
595/655
 
treated cells 
 
2 
 
A
 
595/655
 
 medium)/(
 
A
 
595/655
 
 untreated cells 
 
2 
 
A
 
595/655
 
medium) 
 
3 
 
100.
 
Measurement of Fas Expression, Oxygen Radical Accumulation, Cell
Death, and DNA Histograms by Flow Fluorocytometry.
 
For FACS
 
Ò
 
analysis, cells were kept in suspension by seeding them the day
before in uncoated 24-well tissue culture plates (Sarstedt, Inc.,
Newton, NC).
To visualize cell membrane expression of Fas, cells were
stained with anti-Fas Abs (clone UB-2) and FITC-conjugated
anti–mouse IgG (Harlan Sera-Lab Ltd., Loughborough, Leices-
tershire, UK), and analyzed on a FACScalibur
 
Ò
 
 flow fluorocy-
tometer (Becton Dickinson) equipped with a 488 nm argon ion
laser. FITC fluorescence was detected at 525 nm.
To measure oxygen radical production, DHR123 was added at
the same time as anti-Fas to suspension cultures, and samples were
taken at different time points. PI fluorescence was detected at 610
nm and served as a measure for the percentage of loss of mem-
brane integrity to quantify cell death. R123 fluorescence, as a re-
sult of DHR123 oxidation, was analyzed on intact PI-negative
cells and detected at 525 nm. Relative R123 fluorescence is de-
fined as the ratio of emitted fluorescence at a given time point to
initial fluorescence for the same condition. DNA histograms were
obtained by subjecting the samples to one freeze–thaw cycle in
the presence of PI, and analyzing PI fluorescence of the cells as
described above.
 
Confocal Microscopy.
 
L929 cells were seeded on the day before
measurements on Lab-Tek chambered coverglass (Nunc, Inc.,
Naperville, IL). The next day, zVAD-fmk was added at 25 
 
m
 
M
final concentration, followed 2 h later by the addition of anti-Fas
Abs (500 ng/ml) or TNF (10,000 IU/ml). Before microscopic
analysis, PI was added, and the cells were observed with a confo-
cal microscope (model LSM410; Carl Zeiss, Inc., Thornwood,
NY), using an excitation wavelength of 488 nm and analyzing
through a 610-nm long-pass emission filter.
 
Fluorogenic Substrate Assay for Caspase Activity.
 
Cytosolic cell
extracts were prepared by lysing the cells in a buffer containing
1% NP-40, 200 mM NaCl, 20 mM Tris-HCl, pH 7.4, 10 
 
m
 
g/ml
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leupeptin, aprotinin (0.27 trypsin-inhibitory U/ml), and 100 
 
m
 
M
PMSF. Caspase-like activities were determined by incubation of
cell lysate (containing 25 
 
m
 
g total protein) with 50 
 
m
 
M of the flu-
orogenic substrates acetyl-Tyr-Val-Ala-Asp-aminomethylcoumarin
(Ac-YVAD-amc), acetyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-
aminomethylcoumarin (Ac-DEVD-amc), or benzyloxycarbonyl-
Val-Ala-Asp(OMe)-aminotrifluoromethylcoumarin (zVAD-afc)
(Peptide Institute Inc., Osaka, Japan) in 200 
 
m
 
l cell-free system
buffer, comprising 10 mM Hepes, pH 7.4, 220 mM mannitol,
68 mM sucrose, 2 mM NaCl, 2.5 mM KH
 
2
 
PO
 
4
 
, 0.5 mM EGTA,
2 mM MgCl
 
2
 
, 5 mM pyruvate, 0.1 mM PMSF, and 1 mM dithio-
threitol. The release of fluorescent aminomethylcoumarin or ami-
notrifluoromethylcoumarin was measured for 1 h at 2-min intervals
by fluorometry (Cytofluor; PerSeptive Biosystems, Cambridge,
MA); data are expressed as the maximal rate of increase in fluores-
cence.
 
Western Analysis of Caspase Activation.
 
Cells were treated with
anti-Fas for 0.5 or 2 h, or were left untreated as a control; 7.5 
 
3
 
10
 
6
 
 cells were then lysed in 1 ml lysis buffer (1% NP-40, 10 mM
Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl
 
2
 
, 1 mM PMSF, 0.3 mM
aprotinin, and 1 mM leupeptin). 50 
 
m
 
g total protein was loaded
per lane on 15% SDS-polyacrylamide gels, and after separation
and blotting the different caspase fragments were detected using
polyclonal antisera raised against recombinant murine caspases
and developed by ECL (Nycomed Amersham plc, Little Chal-
font, Buckinghamshire, UK).
 
Measurement of Nuclear Factor 
 
k
 
B Activity.
 
L929 cells carried a
reporter construct consisting of a luciferase gene under control of
the minimal chicken conalbumin promoter preceded by three
nuclear factor 
 
k
 
B (NF-
 
k
 
B) sites (33). Cells were seeded on day
 
2
 
1 at 2 
 
3 
 
10
 
4
 
/microwell. The next day, cells were pretreated
with different caspase inhibitors for 2 h and stimulated with TNF.
After 3 h incubation, cells were lysed according to the luciferase
assay protocol of Promega, Inc. (Madison, WI); luciferin (Duch-
efa Biochemie, Haarlem, The Netherlands) was added, and lu-
ciferase activity was measured on a Topcount Luminometer
(Packard, Meriden, CT).
 
Results
 
Generation of L929 Cells Undergoing Rapid Apoptosis after
Anti-Fas Addition.
 
L929 cells were transfected with the
cDNA encoding human FasR under transcriptional control
of the strong human elongation factor promoter (31). Fas-
transfected L929 cells (hereafter referred to as L929hFas)
were isolated by functional screening. Several clones were
identified that underwent rapid apoptosis after the addition
of anti-Fas mAbs of the IgM isotype (clone CH-11; refer-
ence 34); all of these clones exhibited high expression levels
of Fas at the cell surface. Microscopic examination of anti-
Fas–treated cells showed that the onset of apoptosis, as indi-
cated by membrane blebbing, already started to occur after
30 min, and all cells died after 3 h as detected by flow fluo-
rocytometry of PI-positive cells (Fig. 1). Inhibition of tran-
scription by actinomycin D had no effect on the sensitivity
of the cells or the kinetics of cell death, suggesting that in-
duced protection mechanisms such as A20 (35, 36) are not
relevant in this particular cell clone, in contrast to TNF-
induced cell death, which is highly sensitized and acceler-
ated in the presence of actinomycin D (37, 38).
Figure 1. Rapid induction of apoptosis in L929hFas cells. Cells were
treated with 500 ng/ml of agonistic anti-Fas mAb in the absence (circles)
or presence (triangles) of 1 mg/ml actinomycin D. The fraction of PI-pos-
itive cells was determined in a time-course flow fluorocytometric experi-
ment. Inset, Flow fluorocytometric analysis of Fas expression on Fas-trans-
fected cells (solid line) and mock-transfected cells (broken line).
Figure 2. Determination of
caspase activity in whole cell ly-
sates of L929hFas cells. Cells were
treated with 500 ng/ml of anti-
Fas Ab (A) or 10,000 IU/ml of
TNF (B) in the absence of actino-
mycin D. The cleavage activity,
expressed as maximal fluorescence
increase (max. Dfl.), on Ac-DEVD-
amc (filled circles), Ac-YVAD-amc
(triangles), and zVAD-afc (squares)
was measured as described in Ma-
terials and Methods. Before lysis,
the percentage of PI-positive cells
was determined by flow fluorocy-
tometric analysis (open circles).
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Fas-mediated Apoptosis in L929 Cells Is Associated with Ac-
tivation of Caspase-3 and -7.
 
We investigated whether anti-
Fas treatment of L929hFas cells resulted in induction of
caspase activity. In a first approach, cells were stimulated
for several time periods with anti-Fas, and total cytoplasmic
lysates were incubated with fluorogenic oligopeptide caspase
substrates. No cleavage of Ac-YVAD-amc or zVAD-afc
was observed. However, significant hydrolysis of Ac-
DEVD-amc was detected (Fig. 2 
 
A
 
). These results confirm
that during Fas-mediated apoptosis in L929 cells, caspase-
3–like proteases are rapidly activated.
In a parallel set-up, cell viability was assessed using flow
fluorocytometry to determine the percentage of PI-positive
cells. Maximal Ac-DEVD-amc cleaving activity roughly
corresponded with the onset of loss of membrane integrity.
As cell death progressed in time, Ac-DEVD-amc cleavage
activity decreased rapidly. Presumably, this reflects loss of
active enzyme in the dying cells. As a control, L929hFas
cells were treated with TNF. TNF kills these cells by ne-
crosis, and no caspase activity could be detected after TNF
treatment (Fig. 2 
 
B
 
).
To further identify the caspases involved in Fas-mediated
apoptosis in L929hFas cells, we subjected whole cell lysates of
Fas-treated cells to SDS-PAGE, followed by Western analysis
using polyclonal Abs raised against recombinant murine
caspases. As shown in Fig. 3, cleavage of procaspases-3 and -7
and formation of p17/p18 fragments (39) were observed after
2 h. No cleavage fragments of procaspases-1, -2, -6, -11, or
-12 were detected in the same lysates. This suggests that clus-
tering of Fas very rapidly leads to activation of procaspase-3
and -7. Most probably, activation of procaspase-8 leads
directly to activation of downstream procaspase-3 and –7. In-
deed, the latter caspases are direct substrates of caspase-8 as
demonstrated previously in vitro (22, 23).
 
Oligopeptide Caspase Inhibitors Do Not Block Fas-mediated
Cell Death.
 
Irreversible oligopeptide caspase inhibitors have
been used extensively to study the role of caspases in apop-
tosis. Ac-YVAD-cmk and zDEVD-fmk block caspase-1– and
caspase-3–like proteases, respectively, whereas zVAD-fmk
and zD-fmk are broad-range caspase inhibitors (40–43).
We observed that neither Ac-YVAD-cmk nor zDEVD-
fmk could prevent Fas-mediated L929hFas cell death in an
18-h cytotoxicity assay, even when 100 
 
m
 
M inhibitor was
used. Both zDEVD-fmk and Ac-YVAD-cmk entered the
cells effectively. Pretreatment of the cells with zDEVD-
fmk efficiently blocked cleavage of the fluorogenic sub-
strate Ac-DEVD-amc and poly(ADP-ribose) polymerase.
Moreover, Western analysis of substrate zDEVD-fmk–pre-
treated cells showed an upward shift in M
 
r
 
 of the large sub-
unit of caspase-3 and caspase-7, demonstrating efficient en-
tering into the cells and binding of the inhibitor to caspases
(data not shown). Pretreatment with 100 
 
m
 
M Ac-YVAD-
cmk could inhibit by 70% the TNF-induced release of mu-
rine IL-1
 
b
 
 by L929 cells transfected with the cDNA en-
coding murine pro–IL-1
 
b
 
, thus confirming the capability
of Ac-YVAD-cmk to inhibit caspase-1–like proteases in
L929 cells (data not shown). Surprisingly, both zVAD-fmk
and zD-fmk increased the susceptibility of L929hFas cells
to Fas-mediated cell death by 20-fold, as measured by stain-
ing with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (Fig. 4). Maximal sensitization occurred al-
ready at 25 
 
m
 
M, which suggests that this action is specific.
zAAD-cmk, a granzyme B inhibitor (44, 45), had no effect
on Fas-mediated cell death. Taken together, these results
Figure 3. Western blot analy-
sis of caspases activated in
L929hFas cells after anti-Fas
treatment. Cells were treated
with anti-Fas Ab for 30 min or 2 h,
and whole cell lysates were sub-
jected to PAGE. After blotting,
cleavage products of different
procaspases were detected with
polyclonal rabbit antisera against
the indicated caspases. Pro-
caspase-3 and -7 (32 and 35 kD,
respectively) are processed to a
large subunit (17 and 18 kD, respectively) and a small subunit (no immu-
noreactivity). Caspase-1, -2, -6, -11, and -12 fragments were also ana-
lyzed (in an identical experiment), but no cleavage was detectable.
Figure 4. Effect on Fas-mediated cell death of oligopeptide caspase in-
hibitors in an 18-h assay. 2 h before anti-Fas treatment, 100 mM Ac-
YVAD-cmk (filled circles), 100 mM zDEVD-fmk (open circles), 25 mM
zVAD-fmk (filled triangles), 25 mM zD-fmk (open triangles), 100 mM
zAAD-cmk (filled squares), or medium (open squares) was added. Cell sur-
vival was determined by staining with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide as described in Materials and Methods.
 
Figure 5.
 
Fas-mediated cell death in the absence or presence of zVAD-fmk. Cells were untreated or pretreated with 25 
 
m
 
M zVAD-fmk for 2 h, and
incubated in the presence of 500 ng/ml anti-Fas for the indicated times. As a control for necrotic cell death, cells were exposed to 10,000 IU/ml TNF.
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suggest that even when activation of caspase-3 and -7 is
blocked, Fas clustering still leads to death of L929hFas cells.
Moreover, the broad-range caspase inhibitors sensitized the
cells 
 
z
 
20-fold to anti-Fas. These results are reminiscent of
the sensitization by caspase inhibitors observed in TNF-
mediated necrosis in L929 cells (27).
 
zVAD-fmk and zD-fmk Treatment of L929hFas Cells Re-
veals an Alternative Death Signaling Pathway Originating from
Fas.
 
To study whether the increased sensitivity to Fas-
mediated cell death in the presence of zVAD-fmk or zD-
fmk reflected necrotic cell death, cells were examined mi-
croscopically (Fig. 5). Cells treated for 1 h with anti-Fas
alone clearly showed extensive membrane blebbing. How-
ever, when zVAD-fmk was present, the cells retained the
same morphology as control cells in the absence of anti-
Fas. After 2 h, anti-Fas–treated cells, without caspase inhib-
itors or in the presence of Ac-YVAD-cmk or zDEVD-
fmk, succumbed to apoptotic cell death. Quite surprisingly,
cells incubated in the presence of zVAD-fmk began to ex-
hibit an altered morphology, such as cytoplasmic swelling.
After 3 h, all cells had died in a way that strikingly resem-
bled TNF-mediated necrosis.
To further characterize this alternative Fas-mediated
pathway, the nuclear morphology of TNF-induced necro-
sis and anti-Fas–induced cell death was compared in the
presence or absence of zVAD-fmk. Nuclear morphology
was revealed by PI fluorescence using confocal microscopy
after 3 h of treatment (Fig. 6). When cells were treated
with TNF in the absence or presence of zVAD-fmk, no
chromatin condensation was observed (Fig. 6, 
 
A
 
 and 
 
B
 
), in
contrast to Fas-mediated apoptosis (Fig. 6 
 
D
 
). However, in
the presence of zVAD-fmk, incubation with anti-Fas did
not affect nuclear morphology (Fig. 6 
 
E
 
), as is the case for
TNF-mediated necrosis. Apoptosis is also characterized by
hypoploidy, reflecting the lower DNA content in apop-
totic cells and cell fragments. Fig. 6, 
 
C
 
 and 
 
F
 
, shows DNA
histograms of cells treated with TNF or anti-Fas, respec-
tively. Clearly, TNF treatment of L929 cells does not result
in the formation of hypoploid particles. In contrast, trigger-
ing of Fas antigen gives rise to hypoploid particles. Pre-
treatment with zVAD-fmk completely prevents the ap-
pearance of a hypoploid population after anti-Fas addition,
identical to the outcome of TNF treatment. Hence, when
the apoptotic pathway resulting from Fas triggering is
blocked, a second signaling pathway becomes apparent,
which leads to necrosis and not to apoptosis.
Figure 6. Nuclear morphology and hypoploidy of Fas-mediated cell death. L929hFas cells were preincubated either without (A and D) or with 25 mM
zVAD-fmk (B and E) for 2 h, and treated with 5,000 IU/ml TNF (A and B) or 500 ng/ml anti-Fas (C and D) for another 3 h. PI was added, and nuclear
morphology was analyzed by confocal microscopy. Necrotic nuclei are PI-positive, but retain a normal structural appearance; apoptotic nuclei are char-
acterized by strong condensation of chromatin. C and F show the fraction of hypoploid cell fragments measured as a function of time. Cells were prein-
cubated without (open circles) or with (filled circles) 25 mM zVAD-fmk, and treated with 500 IU/ml TNF (C) or 500 ng/ml anti-Fas (F).
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Fas-mediated Cell Death in the Presence of zVAD-fmk or
zD-fmk Involves Oxygen Radical Production.
 
TNF necrosis
in L929 cells is preceded by an enhanced production of ox-
ygen radicals at the mitochondrial compartment (28, 46,
47). Using DHR123 and flow fluorometry, we examined
whether Fas stimulation of L929 cells actually resulted in
excessive oxygen radical production (Fig. 7 
 
A
 
). Treatment
with anti-Fas alone already induced enhanced radical pro-
duction, rapidly disappearing when the cells lost their
membrane integrity (Fig. 7 
 
B
 
). This drop in R123 fluores-
cence is most probably due to mitochondrial destruction
and loss of mitochondrial transmembrane potential in the
rapidly dying cells. However, in the presence of zVAD-
fmk, a significant rise in R123 fluorescence was observed,
peaking at 
 
z
 
3 h.
Since scavenging of radicals by BHA blocks necrotic cell
death after TNF treatment (28), we tested whether BHA
could also inhibit Fas-mediated necrotic cell death. As
shown in Fig. 7 
 
B
 
, addition of BHA had no significant ef-
fect on Fas-mediated apoptosis. However, in the presence
of zVAD-fmk, a strong delay was observed in the appear-
ance of PI-positive cells, indicating that oxygen radicals are
implicated in cell death induced by anti-Fas in the presence
of caspase inhibitors. Apparently, no difference in PI per-
meability was observed between cells dying by Fas-medi-
ated apoptosis in the absence of zVAD-fmk and by Fas-
induced necrosis in the presence of zVAD-fmk. However,
we observed that in the apoptotic pathway, severe mem-
brane blebbing preceded membrane permeabilization as
measured by PI staining for 
 
.
 
1 h. Indeed, loss of mem-
brane integrity is considered a late phenomenon in apopto-
sis. The mitochondrial radical production could be inhib-
ited to a large extent by the addition of BHA (Fig. 7 
 
A
 
).
Hence, the delay in oxygen radical accumulation observed
in the presence of BHA correlates with the delay in cell
death, as measured by PI uptake. These results strongly
support a mechanism whereby Fas signaling in the presence
of caspase inhibitors leads to necrosis, much like the signal-
ing pathway initiated after TNF treatment of L929 cells
(27, 28).
 
Fas-mediated Necrosis Is Not Accompanied by NF-
 
k
 
B Activa-
tion.
 
Treatment of L929 cells with TNF not only results
in necrotic cell death, but also leads to activation of NF-
 
k
 
B
(48). We wondered whether Fas signaling in the presence
of zVAD-fmk would also lead to NF-
 
k
 
B activation, espe-
cially since enhanced oxygen radicals have been linked
with activation of NF-
 
k
 
B (49). To this end, L929hFas cells
were transfected with a luciferase reporter gene under tran-
scriptional control of three minimal NF-
 
k
 
B sites in tandem
before a minimal promoter (33). As shown in Fig. 8, 2-h
anti-Fas treatment of L929 cells did not result in NF-
 
k
 
B
activation, neither in the absence (as expected) nor in the
presence of zVAD-fmk, despite the high levels of induced
oxygen radicals. TNF-induced NF-
 
k
 
B activation is shown
Figure 7. Fas-mediated cell
death in the presence of zVAD-
fmk is accompanied by oxygen
radical production. L929hFas cells
were untreated or pretreated with
25 mM zVAD-fmk for 2 h, and
incubated with 500 ng/ml anti-
Fas or with anti-Fas and BHA.
Both the oxygen radical produc-
tion (A) and the percentage of PI-
positive cells (B) were determined
under the same conditions.
Figure 8. Fas-mediated necrosis is not accompanied by activation of
NF-kB. L929hFas cells stably transfected with a luciferase reporter gene
were treated for 2 h with 500 ng/ml anti-Fas or 10,000 IU/ml TNF
without or with 25 mM zVAD-fmk (2 h pretreatment). NF-kB activity
was determined by measuring NF-kB–driven luciferase activity.
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as a control. These results indicate that signaling pathways
leading to necrosis and to NF-kB activation are segregated,
and that Fas signaling in the presence of zVAD-fmk only
activates the signals leading to necrotic death. Furthermore,
at least in this particular cell system, a causal relationship
between oxygen radical production and activation of NF-
kB cannot be established. Alternatively, addition of BHA,
which effectively retards TNF-induced necrosis (27), does
not influence TNF-mediated NF-kB activation (data not
shown). This suggests that enhanced mitochondrial oxygen
radical production is not implicated in the activation of
NF-kB. Combined treatment with TNF and anti-Fas in
the presence of zVAD-fmk, resulting in almost complete
cell death after 2 h, does not affect the level of NF-kB ac-
tivity compared with TNF plus zVAD-fmk, excluding the
possibility that rapid cell death would mask Fas-mediated
NF-kB activation.
Fas-mediated Necrosis Does Not Involve Endogenous TNFR.
Fas antigen was originally described as a TNFR-associated
protein (50). Because Fas-mediated necrosis in L929hFas
cells, in the presence of zVAD-fmk, showed characteristics
identical to TNF-mediated necrosis, we wondered whether
during stimulation of the abundantly expressed Fas with
agonistic Abs, TNFR-1 molecules could be cointernalized
or cotrapped, and in this way would initiate the signaling
pathway leading to necrosis. The fact that necrosis in L929
cells after triggering of Fas was not accompanied by activa-
tion of NF-kB already suggested that this was not the case.
To further exclude any kind of association and subsequent
cross talk between both receptors, we expressed human Fas
in L929r1 cells, which are TNF-resistant derivatives char-
acterized by the total absence of TNFRs on the cell surface
(29). Several clones were isolated, many of which showed
Fas expression levels similar to L929hFas. Fig. 9 shows
dose–response curves of L929hFas, compared with an
L929r1.hFas clone expressing similar levels of cell-surface
Fas. When Fas was triggered, the TNF-resistant cells rap-
idly died in an apoptotic way, very much like TNF-sensi-
tive L929hFas cells. In the presence of zVAD-fmk, both
cell types died by necrosis, as was clear from microscopic
examination of cellular and nuclear morphology, and ex-
hibited an increased sensitivity to Fas triggering. Taken to-
gether, these results clearly indicate that Fas triggering in
the presence of zVAD-fmk leads to necrosis independently
of TNFR-1. Conclusively, the signaling leading to necrosis
can be directly activated either by TNFR-1 or by Fas, the
latter occurring when the pathway to apoptosis is blocked
by broad-spectrum caspase inhibitors.
Discussion
The DD-containing TNFR-1 and Fas-R have been
widely studied to unravel the mechanism of apoptosis in-
duction. Regarding Fas-induced apoptosis, the role of
caspases has been documented by the use of caspase inhibi-
tors, by identification of caspase fragments, indicative of
their activation, and by detection of Fas-induced caspase
activity based on cleavage of specific substrates both in vivo
and in cell lysates (20–22, 51–55). But in addition, other
members of the TNFR family, such as WSL-1/death recep-
tor (DR)3/APO-3 (56–58), TNF-related apoptosis–inducing
ligand (TRAIL)-R1/DR4/APO-2 (59), and TRAIL-R2/
DR5/TRAIL receptor inducer of cell killing (Trick)2 (60–
62), contain a DD in their intracellular part, and the cell death
pathway of TRAIL-2R seems to be linked to caspase-10b
(61). L929 cells are killed easily by TNF treatment; the mech-
anism involves enhanced production of reactive oxygen radi-
cals by the mitochondria, which leads to cell death by necro-
sis (28, 46, 47). Clustering of only the DD derived from
TNFR-1 is sufficient to initiate cell death in L929 cells (14).
In this study, we wanted to determine whether, in L929
cells expressing Fas, caspases are activated in the Fas-induced
pathway leading to apoptosis. Using fluorogenic peptide
substrates for caspase activity in cell lysates, we found pro-
teolytic activity only on the tetrapeptide caspase substrate
Ac-DEVD-amc, which correlated very well with the onset
of apoptotic cell death. By Western analysis, only pro-
caspase-3 and -7 were found to be activated after Fas trig-
gering. However, as both caspases are inhibited efficiently
by zDEVD-fmk (41, 63), and Fas-mediated apoptosis in
L929 cells is not, it seems that these proteases are not indis-
pensable for the regulation of apoptosis in L929 cells, but
merely play an executing role in the late stage of apoptosis
by cleaving proteins that are not absolutely required for sig-
naling to apoptosis (7). Like zDEVD-fmk, Ac-YVAD-
cmk, an inhibitor of caspase-1 (and -4/11; references 43
and 53), failed to block Fas-induced apoptosis in L929 cells.
When broad-spectrum pseudosubstrate caspase inhibi-
tors, such as zVAD-fmk and zD-fmk, were added to the
cells before a challenge with anti-Fas Abs, the cells still
Figure 9. Fas-induced necrosis is not mediated by endogenous TNFRs.
L929hFas cells (circles) and TNF-resistant L929r1.hFas cells (triangles) were
subjected to treatment with anti-Fas alone (open symbols) or pretreated
with 25 mM zVAD-fmk (filled symbols). Cell survival was determined after
18 h incubation by staining with 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphe-
nyltetrazolium bromide as described in Materials and Methods.
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died. However, closer inspection of the type of cell death
revealed that at sufficiently high concentrations of inhibi-
tors, apoptosis was indeed inhibited, but now the cells un-
derwent rapid necrotic cell death, as characterized by mor-
phological criteria, such as swelling of the cells, the absence
of nuclear condensation, and the appearance of hypoploid
particles. Furthermore, the generation of oxygen radicals
was identified as the effective mechanism to necrosis.
Therefore, it seems that at least in L929 cells, two different
pathways emerge from the Fas-R: one is caspase-depen-
dent and leads to apoptosis; the other is oxygen radical–
mediated, becomes evident in the presence of caspase in-
hibitors, and results in necrotic cell death.
Caspases that have been reported to be inhibited by
zVAD-fmk are caspase-1 (42, 43), -8 (20, 21), -3, -4/11,
and very weakly caspase-7 (43). The use of the inhibitors
does not allow the pinpointing of caspases involved in the
cell death pathways in L929 cells. Moreover, not only
blocking of a caspase activity but also amplification of oxy-
gen radical production is necessary to reveal the necrotic
Fas pathway. In a previous study, we have shown that
TNF-driven radical production in L929 cells is indeed
strongly enhanced by zVAD-fmk and zD-fmk, and, much
more weakly, by Ac-YVAD-cmk and zDEVD-fmk (27).
Hence, an enhanced oxygen radical production, which is
negatively regulated by zVAD-fmk– and zD-fmk–sensitive
proteases, seems to make the difference between apoptotic
and necrotic outcome of L929 cell death. Further studies
are required to elucidate the relation between caspase inhi-
bition and enhanced radical production.
Necrosis after either TNF or Fas triggering in the pres-
ence of caspase inhibitors involves the production of mito-
chondrial oxygen radicals, which can be shown, for exam-
ple, by the oxidation of DHR123 and the inhibition of
necrosis by the radical scavenger BHA (28). This means
that TNF- and Fas-mediated necrosis converge upstream of
the mitochondria. On the other hand, Fas-mediated necro-
sis is not accompanied by activation of NF-kB, as is the
case with TNF-induced necrosis. Hence, induction of oxy-
gen radical production and activation of NF-kB diverge at
an early point in the TNF-signaling pathway, and it is
downstream of this point that Fas- and TNF-mediated ne-
crosis meet. Previous studies have shown that at least in
some cells, NF-kB activation can be regulated by the redox
state (49). However, in the present study, even though ox-
ygen radical production is prominent when Fas is triggered
in the presence of caspase inhibitors, no NF-kB activation
was observed. This implies that the inability of Fas to medi-
ate NF-kB activation is solely due to its inability to recruit
TRADD, receptor-interacting protein (RIP), and TNFR-
associating factor (TRAF)2, which constitutes the effector
axis leading to NF-kB activation (64). The inability of Fas
to recruit TRADD, RIP, and TRAF2 also implies that
these receptor-associated molecules are not involved in
Fas-mediated necrosis. We propose a dual signaling path-
way emerging from Fas: one is caspase-dependent, leads to
rapid apoptosis, and does not involve production of oxygen
radicals; the second, which under normal conditions is
masked by rapid apoptosis, results in necrotic cell death and
is mediated by massive mitochondrial oxygen radical pro-
duction.
It has been proposed that apoptosis and necrosis might
share common mediators such as Ca21 and caspases (65).
However, at least in the case of L929 cells, clear differences
exist between the two pathways (38). The most striking
difference is that, whereas TNF-mediated necrosis relies on
the production of oxygen radicals as an essential executing
step, Fas-initiated apoptosis does not depend on free radical
production. As shown in this study, the same goes for the
difference between Fas-mediated apoptosis and, in the
presence of the appropriate caspase inhibitors, Fas-mediated
necrosis. Furthermore, even at the top of the signaling
pathway, divergence between apoptotic and necrotic path-
ways is evident. Indeed, whereas Fas-mediated apoptosis is
dependent on recruitment and activation of procaspase-8
(21) or a homologous protease, as shown by the inhibiting
effect of the peptide inhibitors of caspases on apoptosis,
Fas-mediated necrosis, like TNF-mediated necrosis, is not.
Moreover, the broad-spectrum inhibitors zVAD-fmk and
zD-fmk even potently sensitize the necrotic pathway (27).
Hence, to obtain triggering of Fas antigen resulting in mi-
tochondria-dependent necrosis, both inhibition of the caspase-
mediated apoptotic pathway and amplification of the radi-
cal-dependent necrotic pathway are necessary.
Recently, Scaffidi and co-workers (66) described the ex-
istence of two Fas-signaling pathways depending on cell
type. Type I cells are characterized by rapid and massive re-
cruitment of FADD and procaspase-8 into the death-induc-
ing signaling complex, followed 30 min later by activation
of caspase-3, which eventually leads to apoptotic cell death.
Figure 10. Schematic overview of postulated mechanisms for Fas-
mediated cell death. In the absence of inhibitors, the procaspase activation
cascade is triggered, including caspases-3 and -7, and the cells die very
rapidly by apoptosis (type I). However, when signaling to apoptosis is
blocked by caspase inhibitors, secondary signaling components, initiated by
still unknown Fas- or TNFR-1–associated components, induce the mito-
chondria to excessive oxygen radical production (type III). The mecha-
nism of this enhanced oxygen radical production by the addition of
zVAD-fmk is still unclear. One may consider three levels at which a puta-
tive caspase-X might operate: (a) inhibition of signaling to the mitochon-
dria; (b) inhibition of reactive oxygen intermediates (ROI) scavenging;
and (c) removal of damaged mitochondria (reference 27).
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Alternatively, type II cells showed a reduced formation of
the death-inducing signaling complex and delayed activa-
tion of caspase-3 and -8. However, both cell types dis-
played similar kinetics in the loss of mitochondrial trans-
membrane potential and cell death. Overexpression of Bcl-2
or Bcl-xL could prevent this reduction of mitochondrial
transmembrane potential in both type I and II cells, but
could rescue only type II cells from cell death. Hence, in
type II cells, activation of caspases and subsequent cell
death depend on mitochondria, whereas type I signaling is
mediated directly by caspase-8 and -3, the reduction of mi-
tochondrial transmembrane potential being a secondary phe-
nomenon. In view of this model, Fas-mediated apoptosis in
L929 cells can be regarded as type I signaling, involving
rapid activation of the caspase cascade. Fas-triggered necro-
sis, in the presence of caspase inhibitors, and TNF-induced
necrosis may represent an alternate form of signaling to cell
death relying on mitochondrial alterations, the latter result-
ing in enhanced oxygen radical production rather than acti-
vation of caspases. A schematic overview of the proposed
type I and type III signaling components is given in Fig. 10.
The therapeutic use of caspase inhibitors for escaping
unwanted apoptosis is an attractive possibility. For instance,
caspases have already been assigned a role in amyotrophic
lateral sclerosis (67), Alzheimer’s disease (68), and Hunting-
ton’s disease (69, 70). Furthermore, neuronal damage after
hypoxic-ischemic insult (71) or fulminant liver destruction
after anti-Fas injection (72) could be diminished or pre-
vented successfully by the use of peptide caspase inhibitors.
However, the results presented in this paper could restrict
the therapeutic use of caspase inhibitors in that they do not
necessarily guarantee blockage of cell death in general. In
other words, necrotic cell death could at least in some cell
types become evident. Furthermore, cells dying by necro-
sis, instead of apoptosis, may cause an inflammatory re-
sponse. At present, it is not clear which components of the
biochemical machinery make a cell more prone to suc-
cumb to necrosis.
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